Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

49.3K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Scaffold hopping yields novel furo[3,2-<i>d</i>]pyrimidine NNRTIs with optimized antiviral potency, enhanced selectivity, and reduced hERG liability.

Acta pharmaceutica Sinica. B·2026
Same author

Targeted Degradation of Capsid by Host-Hijacking PROTAC Overcomes Drug Resistance.

Journal of medicinal chemistry·2026
Same author

Research Progress and Challenges of Anti-monkeypox Virus Drugs Targeting F13 Protein.

Journal of medicinal chemistry·2026
Same author

Pyridoimidazolyl Sulfonamide Compound <b>2</b>: A Superior Dual-Acting Drug Candidate with Potent URAT1 Inhibition and Anti-Inflammatory Activity for Gout Management.

Journal of medicinal chemistry·2026
Same author

Discovery of 4-Quinazolinone-Containing Phenylalanine Derivatives as Potent, Resistant-Tolerant HIV Capsid Inhibitors.

MedComm·2026
Same author

Discovery of a Novel Thienopyrimidine Derivative as a Potent Dual URAT1/GLUT9 Inhibitor with Enhanced Urate-Lowering Efficacy, Superior Pharmacokinetics, and Favorable Safety Profile for Gout and Hyperuricemia.

Journal of medicinal chemistry·2026

Related Experiment Video

Updated: Jan 17, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.2K

Exploring the HIV-1 Reverse Transcriptase p51/p66 Interface: Structure-Based Design and Optimization of Novel

Xiangkai Ji1, Xiangyi Jiang1, Zhen Gao1

  • 1Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan, Shandong 250012, China.

Journal of Medicinal Chemistry
|September 17, 2025
PubMed
Summary

A novel compound, 15k, shows potent activity against drug-resistant HIV-1 strains. This new non-nucleoside reverse transcriptase inhibitor (NNRTI) offers a promising therapeutic candidate for HIV treatment.

More Related Videos

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.6K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.3K

Related Experiment Videos

Last Updated: Jan 17, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.2K
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.6K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.3K

Area of Science:

  • Medicinal Chemistry
  • Virology
  • Drug Discovery

Background:

  • Growing challenge of HIV-1 drug resistance necessitates novel therapeutics.
  • Existing non-nucleoside reverse transcriptase inhibitors (NNRTIs) face limitations due to resistance.
  • Need for next-generation NNRTIs targeting alternative binding sites.

Purpose of the Study:

  • Design and synthesize novel 2,4,6-trisubstituted pyrimidines as potential anti-HIV-1 agents.
  • Identify compounds with potent activity against wild-type and drug-resistant HIV-1 strains.
  • Investigate the mechanism of action and resistance profile of novel inhibitors.

Main Methods:

  • Chemical synthesis of novel pyrimidine derivatives.
  • Antiviral activity assays against HIV-1 wild-type and mutant strains.
  • Cytotoxicity evaluation.
  • Molecular modeling and docking studies.
  • In vivo pharmacokinetic and safety profiling.

Main Results:

  • Compound 15k demonstrated potent antiviral activity (EC50: 0.0046–0.033 μM) against various HIV-1 strains.
  • 15k exhibited low cytotoxicity (CC50 = 26.64 μM).
  • Molecular modeling revealed a unique 'Y-shaped' conformation of 15k in the NNRTI-binding pocket, forming novel interactions.
  • 15k showed favorable in vivo metabolic stability (T1/2 = 2.12 h) and safety profiles.

Conclusions:

  • Compound 15k is a potent novel non-nucleoside reverse transcriptase inhibitor.
  • 15k displays a promising profile against drug-resistant HIV-1 strains.
  • 15k represents a potential candidate for further development as an anti-HIV-1 therapeutic.